Docetaxel with prednisone or prednisolone for the treatment of ...

128
Appendix 6
Study details and Participant details Intervention details Results Conclusion and
design comments
Outcome 6: Pain
Pain relief: a two-point reduction in the PPI score from
baseline, without an increase in the analgesic score, or vice
versa, maintained for at least 3 weeks
Number evaluated: (n = 464):
I(1), 153; I(2), 154; C,157
Response rate
I(1): 35% (95% CI: 27 to 43, p = 0.01)
I(2): 31% (95% CI: 24 to 39, p = 0.08)
C: 22% (95% CI: 16 to 29)
Duration (median months):
I(1): 3.5 (95% CI: 2.4 to 8.1)
I(2): 5.6 (95% CI: 2.8 to 6.8)
C: 4.8 (95% CI: 4.4 to indeterminate)
Outcome 7: HRQoL
16-point improvement from baseline in the FACT-P score on
two measurements obtained at least 3 weeks apart
Number evaluated (N = 815):
I(1), 278; I(2), 270; C, 267
Response rate:
I(1): 22% (95% CI: 17 to 27, p = 0.009)
I(2): 23% (95% CI: 18 to 28, p = 0.005)
C: 13% (95% CI: 9 to 18)
Withdrawals:
I(1): 3 patients did not receive chemotherapy
I(2): 4 patients did not receive chemotherapy
C: 2 patients did not receive chemotherapy
Discontinuations:
I(1), 38% patients stopped treatment due to progression of
disease, 11% due to adverse events
I(2), 35% patients stopped treatment due to progression of
disease, 16% due to adverse events
C, 56% patients stopped treatment due to progression of
disease, 10% due to adverse events
continued